Davidson Jonathan R T
Department of Psychiatry and Behavioral Science, Duke University Medical Center, Durham, NC 27710, USA.
J Clin Psychiatry. 2006;67 Suppl 2:34-9.
This article reviews pharmacologic treatment options for posttraumatic stress disorder (PTSD), focusing on goals of pharmacotherapy and the clinical trial evidence for drug treatments available for PTSD. The selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line therapy for PTSD; the roles of these and other drug classes including anticonvulsants, mood enhancers, atypical antipsychotic agents, benzodiazepines, alpha1-adrenergic antagonists, and beta-blockers in achieving improvement in PTSD symptom and outcome scores, achieving remission, and avoiding relapse are discussed. Treatment of PTSD in association with other comorbid conditions is addressed, and the role of pharmacotherapy in treating early PTSD and acute stress disorder is examined. Dosing strategies for the SSRIs sertraline and paroxetine are provided, and an algorithm for PTSD pharmacotherapy is discussed.
本文回顾了创伤后应激障碍(PTSD)的药物治疗选择,重点关注药物治疗的目标以及PTSD现有药物治疗的临床试验证据。选择性5-羟色胺再摄取抑制剂(SSRI)被推荐为PTSD的一线治疗药物;文中讨论了这些药物以及其他药物类别(包括抗惊厥药、情绪增强剂、非典型抗精神病药、苯二氮䓬类、α1-肾上腺素能拮抗剂和β-阻滞剂)在改善PTSD症状和结局评分、实现缓解以及避免复发方面的作用。文中还探讨了PTSD合并其他共病的治疗方法,并研究了药物治疗在早期PTSD和急性应激障碍治疗中的作用。提供了SSRI舍曲林和帕罗西汀的给药策略,并讨论了PTSD药物治疗的算法。